Retatrutide
Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Companyprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Atherosclerotic Cardiovascular Disease (ASCVD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eicosapentaenoic Acid Ethyl Ester Kobe University | Phase 4 | BB |
Tirzepatide Brigham and Women's Hospital | Phase 4 | BB |
UMBELLATINE China National Center for Cardiovascular Diseases | Phase 4 | BB |
Maridebart Cafraglutide Amgen | Phase 3 | B |
Inclisiran Novartis Pharmaceuticals | Phase 3 | B |
View all 17 →
Same molecule, other indications
Retatrutide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →